title: A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease.
abstract: Oxidized phospholipids (Ox-PLs) are generated in abundance at sites of inflammation. Recent studies have indicated that Ox-PLs may also exhibit anti-inflammatory activities. In this study, we investigated the beneficial effect of VB-201, a pure synthetic Ox-PL analog that we synthesized, on the development of a central nervous system (CNS) autoimmune inflammatory disease, in vivo. Oral administration of VB-201 ameliorated the severity of experimental autoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein (MOG) peptide MOG35-55, and restrained the encephalogenicity of MOG35-55-specific T-cells. Our data presents a novel prospect for the role of Ox-PL analogs in CNS inflammatory diseases.
authors.affiliation: VBL Therapeutics, 6 Jonathan Netanyahu St., Or Yehuda, 60376, Israel. itzhak@vblrx.com
authors.forename: Itzhak
authors.initials: I
authors.lastname: Mendel
authors.forename: Anat
authors.initials: A
authors.lastname: Shoham
authors.forename: Oshrat
authors.initials: O
authors.lastname: Propheta-Meiran
authors.forename: Eti
authors.initials: E
authors.lastname: Ishai
authors.forename: Gideon
authors.initials: G
authors.lastname: Halperin
authors.forename: Erez
authors.initials: E
authors.lastname: Feige
authors.forename: Eyal
authors.initials: E
authors.lastname: Breitbart
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000187:drug effects; D001973:Bromodeoxyuridine / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects; D004195:Disease Models, Animal; D004347:Drug Interactions; D004660:Encephalitis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000150:complications / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D051858:Forkhead Transcription Factors / Q000378:metabolism; D005620:Freund's Adjuvant / Q000009:adverse effects; D005997:Glycerylphosphorylcholine / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006023:Glycoproteins / Q000009:adverse effects; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D008198:Lymph Nodes / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments / Q000009:adverse effects; D037342:Pertussis Toxin / Q000009:adverse effects; D010767:Phosphorylcholine / Q000031:analogs & derivatives / Q000494:pharmacology; D011109:Polymethacrylic Acids / Q000494:pharmacology; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors
chemical_list: D015704:CD4 Antigens; D016207:Cytokines; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D006023:Glycoproteins; D007476:Ionophores; D063308:Myelin-Oligodendrocyte Glycoprotein; D010446:Peptide Fragments; D011109:Polymethacrylic Acids; C445081:myelin oligodendrocyte glycoprotein (35-55); C500651:poly(MPC-co-MA); D010767:Phosphorylcholine; D015759:Ionomycin; D005997:Glycerylphosphorylcholine; D005620:Freund's Adjuvant; D037342:Pertussis Toxin; D001973:Bromodeoxyuridine; C552500:1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine